Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.

Latest From Ramsey Baghdadi

US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?

Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.

Reimbursement Policy

An Artificial Intelligence Milestone For US FDA

A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.

Artificial Intelligence Drug Approval Standards

Advanced Manufacturing Technology Designation Guidance Uses Broad Criteria For ‘Novel’

In US FDA’s draft, mandated by in the current user fee legislation, contract manufacturers can also vie for a designation. CDER ETT and CBER CATT teams will play a key role in the process.

Guidance Documents Manufacturing

FDA Drug Development Meetings May Be Better Model For Future CMS Patient-Listening Sessions

The ability for Medicare officials to follow-up on patient testimony could make the sessions more informative. They also don’t all have to be the same.

Pricing Debate Medicare

Real-World Views On RWE: RECOVER Trial Seen As US Answer To UK’s RECOVERY

US FDA Commissioner Robert Califf held court with global regulators to discuss the overall state of real-world evidence and how different agencies across the world view it.

Real-World Evidence Clinical Trials

US FDA Office Of Immunology Turnover Tests Updated Review Structure

A leadership transition in FDA’s Office of Immunology & Inflammation will elevate former rheumatology division Director Nikolay Nikolov to the top spot – with a number of interim and inexperienced leaders in the management layers below.

Leadership Drug Review
See All